Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1345/aph.1E653 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovering Severe Adverse Reactions From Pharmacokinetic Drug-Drug Interactions Through Literature Analysis and Electronic Health Record Verification.
Clin Pharmacol Ther
November 2024
Department of Biomedical Informatics, School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
While drug-drug interactions (DDIs) and their pharmacokinetic (PK) mechanisms are well-studied prior to drug approval, severe adverse drug reactions (SADRs) caused by DDIs often remain underrecognized due to limitations in pre-marketing clinical trials. To address this gap, our study utilized a literature database, applied natural language processing (NLP) techniques, and conducted multi-source electronic health record (EHR) validation to uncover underrecognized DDI-SADR signals that warrant further investigation. PubMed abstracts related to DDIs from January 1962 to December 2023 were retrieved.
View Article and Find Full Text PDFRhabdomyolysis associated with concomitant use of colchicine and statins in the real world: identifying the likelihood of drug-drug interactions through the FDA adverse event reporting system.
Front Pharmacol
September 2024
Department of Pharmacy, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
Article Synopsis
- * Using data from the FDA Adverse Event Reporting System, the researchers found 255 reports of rhabdomyolysis linked to the combination of these drugs, indicating a potential drug-drug interaction.
- * The results suggested an increased risk of rhabdomyolysis, especially with atorvastatin and rosuvastatin, urging healthcare professionals to monitor patients closely when prescribing these medications together.
Prognostic factors for colchicine prophylaxis-related adverse events when initiating allopurinol for gout: retrospective cohort study.
Rheumatology (Oxford)
April 2024
School of Medicine, Keele University, Keele, UK.
Objectives: Colchicine is commonly used to prevent flares when starting urate-lowering therapy for gout. Patients with gout are frequently concurrently prescribed other medications (such as statins) that may interact with colchicine, increasing the risk of adverse events. The aim of this study was to describe potential prognostic factors for adverse events in patients prescribed colchicine when initiating allopurinol.
View Article and Find Full Text PDFA case report of colchicine toxicity progressing from diarrhea to rhabdomyolysis: The probable role of interaction with ciprofloxacin.
Int J Rheum Dis
January 2024
Nephrology Clinic, Bingol State Hospital, Bingol, Turkey.
Drugs That Interact With Colchicine Via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS).
Ann Pharmacother
October 2023
Department of Pharmacotherapy, College of Pharmacy, The University of Utah, Salt Lake City, UT, USA.
Background: Colchicine has a narrow therapeutic index. Its toxicity can be increased due to concomitant exposure to drugs inhibiting its metabolic pathway; these are cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp).
Objective: To examine clinical outcomes associated with colchicine drug interactions using the spontaneous reports of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!